EVI1与BCR/ABL基因共表达的儿童白血病临床分析

姜敏; 李小青; 胡东; 张志泉; 杨玉瑶; 白路超; 金润铭

doi:10.7499/j.issn.1008-8830.2014.05.009

PDF(1265 KB)

中国当代儿科杂志 ›› 2014, Vol. 16 ›› Issue (5) : 489-493. DOI: 10.7499/j.issn.1008-8830.2014.05.009

论著·临床研究

EVI1与BCR/ABL基因共表达的儿童白血病临床分析

姜敏^1,3, 李小青², 胡东², 张志泉¹, 杨玉瑶¹, 白路超¹, 金润铭¹

作者信息 +

Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression

JIANG Min^1,3, LI Xiao-Qing², HU Dong², ZHANG Zhi-Quan¹, YANG Yu-Yao¹, BAI Lu-Chao¹, JIN Run-Ming¹

Author information +

文章历史 +

摘要

目的研究EVI1与BCR/ABL基因共表达的儿童白血病的临床特征。方法收集并比较分析4例EVI1与BCR/ABL基因共表达的儿童白血病以及8例BCR/ABL基因表达阳性而EVI1表达阴性的慢性粒细胞性白血病（CML）的临床资料。结果 4例EVI1与BCR/ABL基因共表达的白血病患儿初诊时2例为CML慢性期，1例为CML加速期，1例为高危急性淋巴细胞性白血病（ALL）。3例EVI1与BCR/ABL基因共表达的CML与8例BCR/ABL基因表达阳性而EVI1表达阴性CML临床特征比较无明显差异。EVI1与BCR/ABL共表达的患儿均高表达CD33、CD38。染色体分析发现4例患儿都存在t（9；22）。截止到随访日期2013年8月，3例EVI1基因表达阳性的CML患儿2例在治疗1个月或3个月后达到血液学缓解；2例BCR/ABL基因和EVI1基因均未转阴，1例EVI1基因转阴而BCR/ABL基因仍未转阴。除ALL第一疗程治疗后未达缓解，放弃治疗失访外，其余3例患儿均存活，无复发，总生存期分别为20、13、14个月。结论 EVI1与BCR/ABL融合基因共表达可存在于儿童CML和ALL中，其临床特征无特异性，其预后还需扩大样本量进一步明确。

Abstract

Objective To study the clinical characteristics of ecotopic viral integration site-1 (EVI1) and BCR/ABL positive childhood leukemia. Methods Clinical data of four children with EVI1 and BCR/ABL positive leukemia and eight children with BCR/ABL positive but EVI1 negative chronic myeloid leukemia (CML) were retrospectively analyzed. Results In the four children with EVI1 and BCR/ABL positive leukemia, two were initially diagnosed with chronic phase of CML, one with accelerated phase of CML and one with high-risk acute lymphoblastic leukemia (ALL). There were no significant differences in clinical characteristics at diagnosis between the patients with EVI1 and BCR/ABL positive leukemia and BCR/ABL positive but EVI1 negative leukemia. CD33 and CD38 were highly expressed and t(9;22) abnormality was present in all patients with EVI1 and BCR/ABL positive leukemia. Two of the 3 children with EVI1 and BCR/ABL positive CML achieved complete remission one or three months after treatment. Acquired negative status conversion occurred for EVI1 but not BCR/ABL in one CML case. The 3 children with EVI1 and BCR/ABL positive CML survived 20, 13 and 14 months, respectively, without recurrence. The child with EVI1 and BCR/ABL positive ALL failed to achieve complete remission after the first course of treatment and discontinued further treatment. Conclusions Co-expression of EVI1 and BCR/ABL fusion gene can be found in childhood CML and ALL. The relatively rare leukemia has not significant difference respect to clinical characteristics. Prognosis of the disease needs to be determined by clinical studies with a larger sample size.

导出引用

姜敏, 李小青, 胡东, 张志泉, 杨玉瑶, 白路超, 金润铭. EVI1与BCR/ABL基因共表达的儿童白血病临床分析[J]. 中国当代儿科杂志. 2014, 16(5): 489-493 https://doi.org/10.7499/j.issn.1008-8830.2014.05.009

JIANG Min, LI Xiao-Qing, HU Dong, ZHANG Zhi-Quan, YANG Yu-Yao, BAI Lu-Chao, JIN Run-Ming. Clinical characteristics of childhood leukemia with EVI1 gene and BCR/ABL gene co-expression[J]. Chinese Journal of Contemporary Pediatrics. 2014, 16(5): 489-493 https://doi.org/10.7499/j.issn.1008-8830.2014.05.009

参考文献

[1] Nacheva EP, Grace CD, Brazma D, et al. Does BCR/ABL1 positive acute myeloid leukaemia exist?[J]. Br J Haematol, 2013, 161(4): 541-550.
[2] 姜敏, 吴介洪, 金润铭. EVI1基因在白血病中的研究进展[J].国际儿科学杂志, 2013, 40(4): 398-401.
[3] Toydemir R, Rowe L, Hibbard M, et al. Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes[J]. Cancer Genet Cytogenet, 2010, 201(2): 81-87.
[4] Yagyu S, Morimoto A, Kakazu N, et al. Late appearance of a Philadelphia chromosome in a patient with therapy-related acute myeloid leukemia and high expression of EVI1[J]. Cancer Genet Cytogenet, 2008, 180(2): 115-120.
[5] 王方.儿童急性淋巴细胞白血病治疗效果及预后影响因素的研究[D]. 华中科技大学学位论文, 2012.
[6] Pallisgaard N, Hokland P, Riishoj DC, et al. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia[J]. Blood, 1998, 92(2): 574-588.
[7] Mitelman F. ISCN 1995: An Intemational System for Human Cytogenetic Nomenclature (1995)[M]. Karger Medical and Scientific Publishers, 1995.
[8] 黄绍良,周敦华.小儿血液病临床手册[M].第3版. 北京:人民卫生出版社, 2010: 409.
[9] 顾龙君.儿童急性淋巴细胞白血病诊疗建议（第三次修订草案）[J].中华儿科杂志, 2006, 44(5): 392-395.
[10] Rosenzweig SA. Acquired resistance to drugs targeting receptor tyrosine kinases[J]. Biochem Pharmacol, 2012, 83(8): 1041-1048.
[11] Laurent E, Talpaz M, Kantarjian H, et al.The BCR gene Philadelphia chromosome-positive leukemogenesis[J]. Cancer Res, 2001, 61(6): 2343-2355.
[12] Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification[J]. Science, 2001, 293(5531): 876-880.
[13] Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues[M]. Lyon, France: IARC, 2008.
[14] Cuenco GM, Nicifora G, Ren R. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML[J]. Proc Natl Acad Sci USA, 2000, 97(4):1760-1765.
[15] Cuenco GM, Ren R. Cooperation of BCR-ABL and AML/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia[J]. Oncogene, 2001, 20(57): 8236-8248.
[16] Su E, Han X, Jiang G. The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia[J]. Tumori, 2010, 96(5): 659-666.
[17] Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease[J].Nature Med, 2010, 16(2): 198-204.
[18] Shimada K, Tomita A, Minami Y, et al. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737[J]. Exp Hematol, 2012, 40(9): 724-737.
[19] Paquette RL, Nicoll J, Chalukya M, et al. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors[J]. Cancer Genet, 2011, 204(7): 392-397.
[20] Chen G, Yuan SS, Liu W, et al. Radiation-induced assembly of Rad51 and Rad52 recombination complex required ATM and c-Abl[J]. J Biol Chem, 1999, 274(18): 12748-12752.
[21] 左英熹, 张乐萍, 陆爱东, 等. 具有不同融合基因的B系急性淋巴细胞白血病患儿的临床特征分析[J]. 中国当代儿科杂志, 2010, 12(3): 172-176.
[22] Konantz M, Andre MC, Ebinger M, et al. EVI-1 modulates leukemogenic potential and apoptosis sensitivity in human acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(1): 56-65.